Role of immunohistochemistry and apoptosis as investigative tools in assessing the prognosis of patients with prostate tumours

Miller DC, Hafez KS and Stewart A: Prostate carcinoma presentation, diagnosis and staging: an update from the National Cancer Data Base. Cancer. 98:1169–1172. 2003. View Article : Google Scholar : PubMed/NCBI

Von Eschenbach AC: The biologic dilemma of early carcinoma of prostate. Cancer. 78:326–329. 1996.PubMed/NCBI

Grignon DJ and Hammond EH: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Report of the Prostate Cancer Working Group. Arch Pathol Lab Med. 119:1122–1126. 1995.

Hockenbery D, Nunez C and Milliam C: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:334–338. 1990. View Article : Google Scholar : PubMed/NCBI

Levine AJ: p53, the cellular gatekeeper for growth and division. Cell. 88:323–325. 1997. View Article : Google Scholar : PubMed/NCBI

Issacs JT: Molecular markers for prostate cancer metastasis: developing diagnostic methods for predicting the aggressiveness of prostate cancer. Am J Pathol. 150:1511–1521. 1997.PubMed/NCBI

Grossfeld CD, Olumi AF and Connolly JA: Locally recurrent prostate tumours following either radiation therapy or radical prostatectomy have changes in Ki-67 labelling index, p53 and bcl-2 immunoreactivity. J Urol. 159:1437–1443. 1998. View Article : Google Scholar

Chakravarthi S, Linda TH, Thani PM and Nadeem IB: Role of apoptosis and abnormalities in expression of bcl-2 in benign nodular hyperplasia of prostate. Res J of Biol Sci. 4:836–841. 2009.

Piris MA, Pezzella F and Martinez Montero JC: p53 and bcl2 expression in high grade B-cell lymphomas. Br J Cancer. 69:3371994. View Article : Google Scholar : PubMed/NCBI

Masuda M, Takano Y and Iki M: Prognostic significance of Ki-67, p53 and bcl-2 expression in prostate cancer patients with lymph node metastases: a retrospective immunohistochemical analysis. Pathol Int. 48:41–46. 1998. View Article : Google Scholar

Soini Y and Paakko P: Extent of apoptosis in relation to p53 and bcl-2 expression in germ cell tumors. Hum Pathol. 27:1221–1226. 1996. View Article : Google Scholar : PubMed/NCBI

Shurbaji MS, Kalbfeisch JH and Thurmond S: Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol. 26:106–109. 1999. View Article : Google Scholar : PubMed/NCBI

Prendergest NJ, Atkins MR and Schatte EC: p53 immunohistochemical and genetic alterations are associated at high incidence with post-irradiated locally persistent prostate carcinoma. J Urol. 155:1685–1692. 1996. View Article : Google Scholar : PubMed/NCBI

Cheng L, Sebo JT and Pisanlsky T: p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer. 85:1293–1299. 1999. View Article : Google Scholar : PubMed/NCBI

Fox SB, Persad RA and Royds J: p53 and c-myc expression in stage Al prostatic adenocarcinoma: useful prognostic determinants? J Urol. 150:490–494. 1993.PubMed/NCBI

Kallakury BV, Figge J and Ross JS: Association of p53 immunoreactivity with high Gleason tumor grade in prostatic adenocarcinoma. Hum Pathol. 25:92–96. 1994. View Article : Google Scholar : PubMed/NCBI

Bauer JJ, Sesterhenn IA and Mostofi FK: Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol. 156:1511–1516. 1996. View Article : Google Scholar

Matsushima N, Kitamura T and Goto T: Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma. J Urol. 158:2278–2283. 1997. View Article : Google Scholar : PubMed/NCBI

Bubendorf L, Sauter G and Moch H: Prognostic significance of bcl-2 in clinically localized prostate cancer. Am J Pathol. 148:15571996.PubMed/NCBI